Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Liquidia Technologies, a developer of particle-based vaccines and therapeutics, has signed a collaborative agreement with Path, to develop and conduct preclinical studies on a next generation pneumococcal vaccine against Streptococcus pneumoniae.
Subscribe to our email newsletter
Utilizing a novel technology called Particle Replication In Non-Wetting Templates (PRINT) platform, Liquidia is developing rationally designed carriers for improved delivery of small molecule and biological cargos.
Liquidia Technologies CEO Neal Fowler said by improving vaccine performance and reducing manufacturing costs using its PRINT technology, they hope this collaboration has the potential to impact the spread of pneumonia in the developing world.
Path Pneumococcal vaccine project director Mark Alderson said technologies such as PRINT may help them find safe and effective pneumococcal vaccines that can be delivered to a global population in a cost-effective manner.
"Path is committed to working with scientists and manufacturers to advance vaccines that can prevent the spread of pneumonia and other pneumococcal diseases among children in the developing world," Alderson added.